Cholangiocarcinoma — Expanded Access Programs
Overview
Right2Hope maintains a directory of 32 expanded access programs, clinical trials, and compassionate use pathways listed for Cholangiocarcinoma. Each entry below was sourced from sponsor disclosures and public clinical-trial registries. Use this hub to understand the breadth of ongoing research, identify sponsors with cholangiocarcinoma programs, and link out to specific protocols for eligibility, contact, and request details. Of these, 9 programs are currently active or recruiting, with the remaining 23 in other lifecycle stages. Sponsors actively running programs in this area include National Cancer Institute (NCI), TCR2 Therapeutics, TransThera Sciences (Nanjing), Inc., Apollo Therapeutics Ltd, Beijing InnoCare Pharma Tech Co., Ltd., and others.
By recruiting status
Snapshot of where every Cholangiocarcinoma program currently sits in its lifecycle.
- Active / Recruiting9
- Inactive23
Top sponsors
Organisations running the most Cholangiocarcinoma programs in the directory.
- National Cancer Institute (NCI)5 programs
- TCR2 Therapeutics2 programs
- TransThera Sciences (Nanjing), Inc.2 programs
- Apollo Therapeutics Ltd1 program
- Beijing InnoCare Pharma Tech Co., Ltd.1 program
- Benaroya Research Institute1 program
- Beth Israel Deaconess Medical Center1 program
- Bold Therapeutics, Inc.1 program
- Case Comprehensive Cancer Center1 program
- Cogent Biosciences, Inc.1 program
Cholangiocarcinoma programs (32)
Sorted by recruiting status, then alphabetically by program name. Click any program to view eligibility, locations, and sponsor contact details.
- Study on Using [18F]FAPI-74 PET Imaging for Detecting Cancer — National Cancer Institute (NCI)
- Study on Pembrolizumab with Gemcitabine and Cisplatin for Treating Resectable Intrahepatic Cholangiocarcinoma — M.D. Anderson Cancer Center
- Study on FGFR2/3 Inhibitor (CGT4859) for Patients with Cholangiocarcinoma and Other Advanced Solid Tumors — Cogent Biosciences, Inc.
- Study on Entrectinib for Treating Solid Tumors with Specific Gene Changes — Hoffmann-La Roche
- Study on Nivolumab and Ipilimumab for Treating Patients with Rare Tumors — National Cancer Institute (NCI)
- Study on Olutasidenib for Patients with IDH1 Mutation Positive Cancers — Rigel Pharmaceuticals
- Study on Gavo-cel (TC-210) for Treating Advanced Cancers with Mesothelin Expression — TCR2 Therapeutics
- Study on Trifluridine/Tipiracil and Oxaliplatin for Advanced Biliary Tract Cancer — Case Comprehensive Cancer Center
- Study on Tucatinib with Trastuzumab and Chemotherapy or Pembrolizumab for HER2+ Gastrointestinal Cancers — Seagen, a wholly owned subsidiary of Pfizer
- Study on TC-510 Cell Therapy for Advanced Cancers with Mesothelin Expression — TCR2 Therapeutics
- Phase II Study of Immunotherapy for Advanced Gastrointestinal Cancers with KRAS or TP53 Mutations — National Cancer Institute (NCI)
- Study on CTX-009 and Paclitaxel for Advanced Biliary Tract Cancers — Compass Therapeutics
- Study on ICP-192 for Patients with Advanced Solid Tumors — Beijing InnoCare Pharma Tech Co., Ltd.
- Study on Adding LSTA1 to Standard Treatment Versus Standard Treatment Alone for Advanced Solid Tumors — Lisata Therapeutics, Inc.
- Study on Using Medtronic Pump and Codman Catheter for Chemotherapy in Patients with Colorectal or Bile Duct Cancer — Benaroya Research Institute
- Study on APL-5125 for Adults with Advanced Solid Tumors — Apollo Therapeutics Ltd
- Study on Using Tumor Infiltrating Lymphocytes for Treating Biliary Tract Cancers — Udai Kammula
- Study on BOLD-100 with FOLFOX for Treating Advanced Solid Tumors — Bold Therapeutics, Inc.
- Study on Combining GNS561 and Trametinib for Patients with Advanced KRAS Mutation Cholangiocarcinoma — Genfit
- Domvanalimab and Zimberelimab in Advanced Liver Cancers — University of Texas Southwestern Medical Center
- Early Access Program for HER2/HER3 Bispecific Antibody MCLA-128 for Patients with Advanced NRG1-Fusion Positive Solid Tumors — Merus N.V.
- Study on the Effectiveness of Tivozanib in Treating Biliary Tract Cancers — National Cancer Institute (NCI)
- Study on the Duration of PD-1/PD-L1 Inhibitor Treatment in Advanced Solid Tumors — Jason J. Luke, MD
- Access Program for Advanced Cholangiocarcinoma Treatment with ABC294640 (Yeliva ®) — RedHill Biopharma Limited
- Expanded Access to Ulixertinib (BVD-523) in Patients with Advanced MAPK Pathway-Altered Malignancies — xCures
- Study on M9241 with Liver-Directed Chemotherapy and Systemic Therapy for Patients with Liver Metastases from Colorectal Cancer or Bile Duct Cancer — National Cancer Institute (NCI)
- Rollover Study to Provide Continued Access to TT-00420 (Tinengotinib) for Subjects With Advanced Solid Tumors — TransThera Sciences (Nanjing), Inc.
- Study on Gemcitabine, Cisplatin, AB680, and AB122 for First-Line Treatment of Advanced Biliary Tract Cancers — Nataliya Uboha
- Study on NGM707 Alone and with Pembrolizumab for Advanced or Metastatic Solid Tumors — NGM Biopharmaceuticals, Inc
- Study of Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors — Merck Sharp & Dohme LLC
- Study Comparing Tinengotinib to Doctor's Choice for Treating Cholangiocarcinoma with FGFR Changes — TransThera Sciences (Nanjing), Inc.
- Study on Y-90 Radiation, Durvalumab, Gemcitabine, and Cisplatin for Bile Duct Cancer — Beth Israel Deaconess Medical Center
About this hub
Expanded access programs (sometimes called compassionate use, named-patient programs, or pre-approval access) allow patients with serious or life-threatening conditions such as Cholangiocarcinoma to receive an investigational therapy outside of a controlled clinical trial when no comparable approved option is available. Eligibility, location, and the application process differ for each program — review the individual program pages below for sponsor contact information, inclusion criteria, and the request workflow. Right2Hope is a 501(c)(3) nonprofit and provides this directory free of charge for patients, caregivers, and treating physicians.
Looking for a different condition? Browse the full Cancer Type hub directory or search the full expanded access program catalog.